CLDN18 positive

CI-VAR-00005041Explore in graph →CIViC 5067

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Gastric Adenocarcinoma2
CLDN18 positive	CAPOX Regimen + ZolbetuximabCombination	Predictive	A	Supports Sensitivity Response	5	submitted	EID12216 In the phase 3 GLOW trial (NCT03653507), 507 patients with CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma were randomized 1:1 to receive either zolbetuximab combined with CAPOX … (full text at CIViC) PMID 37524953 · Shah et al., 2023 · Open in CIViC	civic
CLDN18 positive	FOLFOX-6 Regimen + ZolbetuximabCombination	Predictive	A	Supports Sensitivity Response	4	submitted	EID12215 In the phase 3 SPOTLIGHT trial (NCT03504397), 565 patients with gastroesophageal junction adenocarcinoma were randomized to receive either zolbetuximab combined with mFOLFOX6 (n=283) or placebo with m… (full text at CIViC)

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.